Speaker
Philipp Altrock
(MPI for Evolutionary Biology & UKSH)
Description
Chimeric Antigen Receptor (CAR) T-cell therapy has emerged as a promising option for relapsed or refractory lymphoma patients and acute leukemias. Mathematical modeling offers a valuable tool for investigating the interactions among these living drugs, tumors, and heterogeneous patients' immune or inflammatory context. Using longitudinal data from experiments and the clinic, we examine how diverse CAR T cell phenotypes interact with heterogeneous tumors, how these interactions can be inferred, and how they impact outcomes.
Primary author
Philipp Altrock
(MPI for Evolutionary Biology & UKSH)
